FUJIFILM Corp.’s Life Sciences Group companies announced new names and identities as part of a strategic positioning effort. The Group Companies’ new names, collaborative strategic focus, and structural alignment reflects the compnay’s integrated services across drug development, from research and discovery to clinical and commercial manufacturing.

FUJIFILM Irvine Scientific, headquartered in Santa Ana, CA rebrands as FUJIFILM Biosciences to reflect its recent expansion to serve broader life sciences communities and customers. It also references its scientific roots in the cell culture media industry. Today, FUJIFILM Biosciences offers a portfolio of discovery and research reagents, recombinant growth factors and proteins, specialty chemicals, and critical assay materials in addition to its cell culture media and supplements solutions in the U.S. 

FUJIFILM Diosynth Biotechnologies, a global CDMO, first acquired by the Fujifilm Group in 2011, rebrands to FUJIFILM Biotechnologies, offering capabilities for process development through commercial supply, with manufacturing operations across Europe, and the U.S.

Over the past 15 years, Fujifilm has invested more than $10 billion through expansions and acquisitions to build its life sciences capabilities.

Alongside FUJIFILM Biosciences and FUJIFILM Biotechnologies, the Fujifilm Life Sciences Group companies also include FUJIFILM Cellular Dynamics, a developer and manufacturer of human induced pluripotent stem cells, FUJIFILM Wako Pure Chemical Corp., and FUJIFILM Toyama Chemical Co., Ltd.